Bloom Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.93 M
- Company Age 21 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 3.40 M
- Revenue Growth 4.29%
- Profit Growth -71.28%
- Ebitda -77.79%
- Net Worth -3.16%
- Total Assets 28.57%
About Bloom Pharma
Bloom Pharma Private Limited (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 23 December 2003 and has a history of 21 years and one month. Its registered office is in Nashik, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.93 M.
The company has closed loans amounting to ₹3.40 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Narendra Sonawane, Atul Shinde, Nutan Rajbhoj, and Two other members serve as directors at the Company.
Company Details
-
Location
Nashik, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230MH2003PTC143607
-
Company No.
143607
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
23 Dec 2003
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Bloom Pharma?
Board Members (5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narendra Sonawane
|
Director | 23-Dec-2003 | Current |
|
Atul Shinde
|
Director | 23-Dec-2003 | Current |
|
Nutan Rajbhoj
|
Director | 23-Dec-2003 | Current |
|
Karan Sonawane
|
Director | 04-Jul-2011 | Current |
|
Sandhya Sonawane
|
Director | 04-Jul-2011 | Current |
Financial Performance of Bloom Pharma.
Bloom Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 4.29% increase. The company also saw a substantial fall in profitability, with a 71.28% decrease in profit. The company's net worth dipped by a decrease of 3.16%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bloom Pharma?
In 2023, Bloom Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0
₹3.40 M
Charges Breakdown by Lending Institutions
- Uco Bank : 0.34 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Jan 2009 | Uco Bank | ₹2.50 M | Satisfied |
| 14 Dec 2004 | Uco Bank | ₹0.90 M | Satisfied |
How Many Employees Work at Bloom Pharma?
Bloom Pharma has a workforce of 1 employees as of Mar 27, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bloom Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bloom Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.